Trial: 201505024

An Open-Label, Multicenter, Phase I/II trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined with Atezolizumab in patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia

Phase

I

Principal Investigator

Bartlett, Nancy

Disease Site

Chronic Lymphocytic Leukemia (CLL); Lymphoid Leukemia; Non-Hodgkin’s Lymphoma

Learn more about this study at: clinicaltrials.gov